32 results about "Sialyl LeA" patented technology

In a method for treating cancer by desialylation of sialylated glycans expressed on the surface of cancer cells, the present invention provides a method for extending the serum half-life of the active ingredient, sialidase, and enhancing the therapeutic effect of said sialidase. [Solution] A pharmaceutical composition is provided that contains sialidase which, when administered to a subject, conjugates to a serum half-life enhancing factor that increases the serum half-life of sialidase.

The present invention provides a drug delivery system for penetrating the blood-brain barrier, which is obtained by binding sialyllactose, which is capable of penetrating the blood-brain barrier, to a drug. The drug delivery system can deliver not only small molecular weight drugs, but also antibodies, which have a large molecular weight, to the brain, and is therefore applicable to various brain disease treatments and diagnostic substances.

A method of treating an aging-related disorder includes identifying a subject having an aging-related disorder and administering to the subject a therapeutically effective amount of a desialylated O-glycosylated glycoprotein, wherein the therapeutically effective amount is between 0.1 mg / kg and 500 mg / kg with respect to a body weight of the subject. Also disclosed are methods for producing the desialylated O-glycosylated glycoprotein using a clonal cell lacking sialyltransferase activity.

The present invention relates to a composition for promoting intestinal development and its use. The composition comprises lactose-N-neotetraose and 3'-sialyllactose. The composition for promoting intestinal development according to the present invention can upregulate the transcription levels of intestinal glycocalyx development-related genes HAS1, HAS2, and HAS3, as well as the transcription level of EXT2, thereby synergistically promoting intestinal glycocalyx development.

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.

To provide a method for treating a patient by using an IgG pharmaceutical highly added with sialic acid.SOLUTION: A method for treating a disease includes administering an hsIgG pharmaceutical to a subject by 1% to 10% dosage of an effective dosage of IVIG in order to treat the disease.SELECTED DRAWING: None

To provide nucleic acids encoding human antibodies to Sialyl-Lewis a.SOLUTION: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa(sLea). The compositions of the invention include polynucleotides encoding a heavy chain and / or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation. The antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that have an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.SELECTED DRAWING: Figure 1

The invention discloses a kit for detecting plasma IgG glycosylation level and a detection method thereof, and relates to the technical field of biological detection.Plasma IgG is specifically captured through protein A, four biotinylation lectins are combined, sialylation, galactosylation, fucosylation and mannosylation levels of IgG can be synchronously and quantitatively detected, a standardized ELISA system is established, and the kit is used for detecting the plasma IgG glycosylation level. Operation is easy and convenient, repeatability is good, and the problem that multi-dimensional simultaneous detection cannot be achieved in the prior art is solved. The kit is low in cost, does not need complex instruments, is suitable for large-scale clinical popularization, and fills the market blank of commercial IgG glycosylation ELISA kits. Clinical samples of colorectal cancer prove that patients and healthy people can be effectively distinguished, in-vitro risk assessment can be realized by combining a column diagram model, the detection efficiency is excellent, and the method can be expanded to be applied to assessment and monitoring of various tumor and inflammation related diseases, and has high clinical value.

The present invention provides isolated monoclonal antibodies that specifically bind to Sialyl Lewis A (SLeA) glycan, fragments thereof and humanized version of said antibodies or fragments, as well as conjugates thereof. The invention further provides chimeric antigen receptors comprising said antibodies or fragments and cells, such as T cells comprising same. The invention further provides pharmaceutical compositions comprising all of the above agents and use of said agents and compositions for diagnosing and treating cancer characterized by overexpression of SLeA.

Methods of treating an autoimmune disorder affecting the skin and / or the kidneys, e.g., epidermal bullosa acquisita (EBA) or glomerulonephritis in a human subject thereof, using a population of highly sialylated immunoglobulin Fc polypeptides having an amino acid substitution from phenylalanine to an aliphatic amino acid residue, such as alanine, at amino acid residue 241 of the Fc heavy chain.

The present disclosure provides compositions and methods related to chimeric antigen receptors (CARs). In particular, the present disclosure provides CAR-based immunotherapeutic compositions targeting GM2-expressing tumor cells for the treatment and prevention of cancer.

A method for predicting curative effect of glioblastoma and preparing related drugs belongs to the field of biological medicine, and characterizes N-glycome spectrums in a cerebrospinal fluid sample paired before and after treatment of a glioblastoma patient by using a hydrophilic interaction liquid chromatography combined fluorescence detection and mass spectrometry technology. After chromatographic and mass spectrometric data are analyzed by a computer, the treatment effect of glioblastoma, especially the treatment effect of apatinib, can be predicted or judged through changes of LacdiNAc, sialylation level and core fucosylation level, guidance is provided for a patient to select a treatment scheme, and the method can be used for preparing a medicine for treating glioblastoma.

The invention discloses a chimeric transformation receptor based on a macrophage immune checkpoint Siglec9 and application of the chimeric transformation receptor. The chimeric transformation receptor comprises an extracellular domain, a transmembrane domain and an intracellular domain, the extracellular domain is an extracellular structural domain of a human Siglec9 receptor or functional homologues of other species; the transmembrane domain is a transmembrane structural domain of CD8 or CD28; the intracellular domain is selected from the group consisting of intracellular signaling domains of CD3 [zeta], FcR [gamma], TLR4, CD40, Megf10, Dectin-1, or a combination thereof. The chimeric transformation receptor based on the macrophage immune checkpoint Siglec9 is expressed on the surface of the macrophage, so that after sialic acid glycan on the surface of a tumor cell is combined with the chimeric transformation receptor on the surface of the macrophage, the macrophage is driven to be transformed into an anti-tumor M1 phenotype; the engineering macrophages are promoted to always keep an effective killing capability state on tumor cells, and the killing effect of an immune cell therapy on the tumor cells is exerted and amplified, so that an efficient and lasting anti-tumor effect is obtained.

The present invention relates to a method for producing α-2,6-sialylated immunoglobulin using plasma cells isolated from humans. The present invention makes it possible to mass produce α-2,6-sialylated immunoglobulin (2,6 IG) without using human blood, and it was discovered that α-2,6-sialylated immunoglobulin (2,6 IG) produced by the present invention can increase the level of IL-10, which is representative of an immunosuppressive cytokine produced by DC-SIGN stimulation. Thus, the method according to the present invention can be effectively used as an immunoglobulin substitute capable of replacing IVIG.

Methods, uses and compositions including rFSH including α2,3- and α2,6-sialylation for use in the treatment of infertility in a male patient are described.

To provide an alternative antibody therapy targeting glycan epitopes.SOLUTION: Provided is an antibody or antigen-binding portion thereof that binds to sialyl Lewis A (sLeA) and sialyl Lewis C (sLeC), wherein the binding affinity of the antibody or antigen-binding portion to sLeA is a KD of 60 μ M or less and the binding affinity to sLeC is a KD of 100 μ M or less. Also provided are polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.SELECTED DRAWING: Figure 2C

The invention provides application of an N-glycan marker, a fetal and neonatal hemolytic disease prediction model and a fetal and neonatal hemolytic disease prediction device. The following characteristics (a) or (b) of pregnant woman plasma N-glycan serve as the marker for predicting fetal and neonatal hemolytic diseases: (a) abundance of one or more sugar chain types: H5N4S2, H4N5F, H5N5S2, H6N5S2, H6N5S3 and H6N5FS3; (b) abundance of one or more of the following glycosylation characteristics: high branch structure, low branch structure, tri-sialylation, tri-galactosylation, double-galactosylation, outer arm fucosylation. The marker has a significant difference in HDFN and non-HDFN pregnant woman plasma, and can be used as a marker for predicting the fetal and neonatal hemolytic diseases, and a prediction model constructed based on the marker can accurately predict whether a subject suffers from the fetal and neonatal hemolytic diseases or judge the risk of the subject suffering from the fetal and neonatal hemolytic diseases.

Glycopeptides derived from short CD44 isoforms lacking amino acids encoded by exons 6-14; presenting one or multiple serine or threonine residues substituted with Tn (GalNAcα-O-Ser / Thr) and / or sialyl-Tn (STn; Neu5Acα2-6GalNAcα-O-Ser / Thr) antigens. Synthesizing the glycopeptides, including one-pot glycosylation of synthetic short isoform CD44 peptides through combination with nucleotide sugars and glycosyltransferases and purification of CD44s-Tn glycopeptides. Immunogenic chimeras derived from the CD44-Tn and / or STn glycopeptides, linked, in polyvalent form, to a carrier immunogenic protein, e.g., KLH CRM197. Conjugating the synthesized CD44s-Tn glycopeptides to the immunogenic protein carriers CRM197 and KLH, generating chimeric glycopeptides, termed CRM197-CD44s-Tn and KLH-CD44s-Tn. CD44-Tn / STn glycopeptides or compositions thereof for treating cancer and pre-neoplastic diseases, e.g., neoplastic diseases expressing short CD44 isoforms, through generating antibodies against cancer cells and treating / preventing cancer by vaccination. The glycopeptides, compositions, synthesis methods and uses can be employed in treating cancer, alone or in combination with immune checkpoint inhibitor therapy, chemotherapy, and radiotherapy.

This disclosure is based, at least in part, on an unexpected discovery that coexpression of both type I Fc receptor (e.g., FcyRIIB) and type II Fc receptor (e.g., DC-SIGN) augments the binding of IVIG and its active component, sialylated Fc. The disclosed Fc variants can achieve a significant enhancement of in vivo protection as compared to IVIG in several models of autoantibody mediated inflammation.

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragment or biologically active sialylated variant thereof. The invention also relates to methods of producing such proteins in vitro, and methods of using such proteins for the treatment of complement-mediated diseases, such as C3 glomerulopathy, atypical hemolytic uremic syndrome or age-related macular degeneration.

The invention relates to a method of quantifying sialylated IgE in a test sample, the method comprising: immobilising sialylated IgE in the test sample via a capture probe which is specific for sialylated glycoproteins, wherein the capture probe is immobilised; and using an antibody-based detection technique to quantify sialylated IgE. The invention further relates to: diagnosis of allergy in a subject, methods of treatment comprising diagnosis of allergy followed by treatment by immunotherapy, kits comprising reagents for the method, and use of the kits to quantify sialylated IgE in a test sample.

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of polysialic acid. The antibodies of the present technology are useful in methods for detecting and treating a polysialic acid-associated cancer in a subject in need thereof.

The present application relates to antigen-binding proteins that bind Sialyl-Thomsen-nouveau antigen. The antigen-binding proteins find application in the treatment of diseases and disorders, such as cancer.

The present invention belongs to the field of biotechnology and provides a method and application for improving the sensitivity and specificity of anti-CA724 antibodies. The method of improving the sensitivity and specificity of anti-CA724 antibodies of the present invention specifically comprises: enzymatically cleaving the anti-CA724 antibodies with sialylase to obtain desialylated anti-CA724 antibodies, thereby improving the sensitivity and specificity of the anti-CA724 antibodies. The present invention transforms conventional anti-CA724 antibodies through an enzymatic cleavage process, thereby improving the sensitivity and specificity of the anti-CA724 antibodies and effectively reducing detection costs.

Disclosed are methods of preparing 3-fluorosialic acid-containing sugars, and methods of conjugating the same to homogeneous antibodies. Also within the scope of the invention are 3-fluorosialic acid-containing compounds, monoclonal antibodies conjugated to N-glycans terminating in 3-fluorosialic acid glycosides linked in an alpha 2,6 configuration, and methods of using such monoclonal antibodies to treat cancer.

summary The present invention relates to in vitro sialylated human factor H protein, or to biologically active sialylated fragments or biologically active sialylated variants thereof. The present invention also relates to methods for producing such proteins in vitro, and to methods for using such proteins in the treatment of complement-mediated diseases such as C3 glomerulosis, atypical hemolytic uremic syndrome, or age-related macular degeneration.

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.

This disclosure is based, at least in part, on an unexpected discovery that coexpression of both type I Fc receptor (e.g., FcyRIIB) and type II Fc receptor (e.g., DC-SIGN) augments the binding of IVIG and its active component, sialylated Fc. The disclosed Fc variants can achieve a significant enhancement of in vivo protection as compared to IVIG in several models of autoantibody mediated inflammation.

Provided are a method of identifying a sialic acid binding immunoglobulin-type lectin (Siglec) -binding molecule possessing cis-trans converter properties upon binding to the Siglec; a vector comprising a nucleic acid molecule encoding an Siglec-binding molecule and a nucleic acid molecule encoding the Siglec; a host cell comprising the vector; an anti-CD22 antibody; a pharmaceutical composition comprising the anti-CD22 antibody and a pharmaceutically acceptable excipient, diluent or carrier; a method of preventing or treating an autoimmune disease or a neurological disease; and a method of identifying a sialic acid binding immunoglobulin-type lectin (Siglec)-binding molecule lacking cis-trans converter properties upon binding to the Siglec.